SavedAdd your journal

Journals / İstanbul Kuzey Klinikleri / 2022 / Cilt: 9 - Sayı: 1

Bone biochemical markers in acromegaly: An association with disease activity and gonadal status

Mehmet Emin PİŞKİNPAŞA
Hamide PİŞKİNPAŞA
Pages
74–81
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

RESULTS: The calcium, phosphorus, and CTX were increased in the acromegaly group compared to the control group (p=0.04, p=0.006, and p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: We aim to demonstrate the effect of disease activity and gonadal status on bone biochemical parameters in patients with acromegaly.
📊
Key Findings & Data:METHODS: In this cross-sectional,case–control study, 73 patients with acromegaly and 64 healthy controls were included in the study.
💡
Conclusion & Impact:RESULTS: The calcium, phosphorus, and CTX were increased in the acromegaly group compared to the control group (p=0.04, p=0.006, and p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: We aim to demonstrate the effect of disease activity and gonadal status on bone biochemical parameters in patients with acromegaly. METHODS: In this cross-sectional,case–control study, 73 patients with acromegaly and 64 healthy controls were included in the study. Acromegaly and control groups, as well as active/controlled acromegaly groupswere compared in terms of alkaline phosphatase (ALP), calcium, magnesium, phosphorus, parathormone (PTH) and 25-OH Vitamin D (25[OH]D), and C-terminal telopeptide of type 1 collagen (CTX). Patients with hypogonadism and normal gonadal status were also compared in terms of these parameters among patients with acromegaly. RESULTS: The calcium, phosphorus, and CTX were increased in the acromegaly group compared to the control group (p=0.04, p=0.006, and p

🔖

Cite This Article

PİŞKİNPAŞA, M. E., PİŞKİNPAŞA, H. (2022). Bone biochemical markers in acromegaly: An association with disease activity and gonadal status. İstanbul Kuzey Klinikleri, Cilt: 9 - Sayı: 1, 74–81. https://ajindex.com/articles/551225

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al; Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3933–51
  2. Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013;16:294–302
  3. Lieberman SA, Björkengren AG, Hoffman AR. Rheumatologic and skeletal changes in acromegaly. Endocrinol Metab Clin North Am 1992;21:615–31
  4. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008;29:535–59
  5. Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2015;100:384–94
  6. Ueda M, Inaba M, Tahara H, Imanishi Y, Goto H, Nishizawa Y. Hypercalcemia in a patient with primary hyperparathyroidism and acromegaly: distinct roles of growth hormone and parathyroid hormone in the development of hypercalcemia. Intern Med 2005;44:307–10
  7. Manroa P, Kannan S, Hatipoglu B, Licata A. Hypercalcemia and acromegaly- clarifying the connections. A case report and review of the literature. Endocr Pract 2014;20:e86–90
  8. Menaa C, Vrtovsnik F, Friedlander G, Corvol M, Garabédian M. Insulin- like growth factor I, a unique calcium-dependent stimulator of 1,25-dihydroxyvitamin D3 production. Studies in cultured mouse kidney cells. J Biol Chem 1995;270:25461–7
  9. Nesbitt T, Drezner MK. Insulin-like growth factor-I regulation of renal 25-hydroxyvitamin D-1-hydroxylase activity. Endocrinology 1993;132:133–8
  10. Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, Schoenfeld DA, et al. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf ) 2001;54:183–8
  11. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95:3141–8
  12. Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009;360:606–14
  13. Nelson HD. Menopause. Lancet 2008;371:760–70
  14. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018;103:1715–44
  15. Altinova AE,